GB2525626A - Composition and method for inhalable nutritional element - Google Patents
Composition and method for inhalable nutritional element Download PDFInfo
- Publication number
- GB2525626A GB2525626A GB1407554.3A GB201407554A GB2525626A GB 2525626 A GB2525626 A GB 2525626A GB 201407554 A GB201407554 A GB 201407554A GB 2525626 A GB2525626 A GB 2525626A
- Authority
- GB
- United Kingdom
- Prior art keywords
- nutrient
- compound
- content
- nutritional
- vaporizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000016709 nutrition Nutrition 0.000 title claims description 20
- 238000000034 method Methods 0.000 title description 8
- 239000000203 mixture Substances 0.000 title description 4
- 235000015097 nutrients Nutrition 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 235000013343 vitamin Nutrition 0.000 claims abstract description 12
- 239000011782 vitamin Substances 0.000 claims abstract description 12
- 229940088594 vitamin Drugs 0.000 claims abstract description 12
- 229930003231 vitamin Natural products 0.000 claims abstract description 12
- 238000009792 diffusion process Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000006200 vaporizer Substances 0.000 claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 5
- 230000000241 respiratory effect Effects 0.000 claims abstract description 5
- 239000000443 aerosol Substances 0.000 claims abstract description 4
- 239000003792 electrolyte Substances 0.000 claims abstract description 4
- 239000003925 fat Substances 0.000 claims abstract description 3
- 235000010755 mineral Nutrition 0.000 claims abstract description 3
- 239000011707 mineral Substances 0.000 claims abstract description 3
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 3
- 239000006199 nebulizer Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims abstract 4
- 210000002345 respiratory system Anatomy 0.000 claims abstract 3
- 150000001720 carbohydrates Chemical class 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 238000010521 absorption reaction Methods 0.000 claims description 12
- -1 dietary minerals Chemical class 0.000 claims description 2
- 230000003050 macronutrient Effects 0.000 claims description 2
- 235000021073 macronutrients Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000011785 micronutrient Substances 0.000 claims 1
- 235000013369 micronutrients Nutrition 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000008016 vaporization Effects 0.000 claims 1
- 150000002484 inorganic compounds Chemical class 0.000 abstract 1
- 229910010272 inorganic material Inorganic materials 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003571 electronic cigarette Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 241000242759 Actiniaria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000003892 absorptive cell Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008249 pharmaceutical aerosol Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002978 thoracic duct Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound comprising at least one or more organic or inorganic nutrient and/or electrolyte which is formulated for inhalation into the respiratory system. Preferably the nutrient compound is of a form that is easily absorbed into the blood stream by diffusion through the respiratory system. The compound may be insufflate nasally and absorbed through the mucous membrane. The compound may be in powder or liquid form, and carried to the respiratory passages by devices such as an aerosol, nebulizer or vaporizer. The nutrient components particles are preferably 5-10 um in diameter or less. The compound can be supplied alongside conventional medicine. The organic nutrient may include carbohydrate, fats, protein (or amino acids), and vitamins and inorganic compounds such as dietary minerals.
Description
Composition and Method for Inhalable Nutritional Element
FIELD OF THE INVENTION
The present invention pertains to the composition and method for a nutritional content component containing elements in a form that can be administered by the inhaled route S for direct passive exchange by diffusion between the gaseous external environment of the respiratory track and the blood of a human being.
BACKGROUNG OF THE INVENTION
Humans must consume vitamins periodically but with differing schedule to avoid deficiency. Deficiencies of vitamins are classified as either primary or secondary. A primary deficiency occurs when an organism does not get enough of the vitamin in its food. A secondary deficiency may be due to an underlying disorder that prevents or limits the absorption or use of the vitamins due to a lifestyle factor, such as smoking, alcohol consumption or the use of medications that interfere with the absorption or the use of vitamins. Vitamins deficiencies have the potential to cause prolonged and potentially deadly diseases.
There are a wide range of different conditions that can produce malabsorption in the gastrointestinal tract and often, replacement of nutrients, electrolyte and fluid may be necessary. Also conventional oral administration can be prohibited by nausea. In severe deficiency, hospital admission may be required for nutritional support. Use of enteral nutrition by nas-gastric or other feedings tubes may be required to provide sufficient nutritional supplementation. Treatment for malabsorption is directed largely towards management of underlying cause.
In the gastro-intestinal (01) tract, the intestinal villi are responsible for absorption. There are small, anemones like protrusion from the epithelial lining of the intestinal wall. Villi increase the internal surface area of the intestinal walls which increase absorption.
Increased absorptive area is useful because digested nutrients (including monosaccharide and amino acids) pass into the semipermeable villi through diffusion.
The villi are connected to the blood vessels so the circulating blood then carries these nutrients away. Equally, the lungs have a total surface area of about 70 square meters in adults to increase absorption of the inhaled air through diffusion where oxygen moves from the alveoli to the blood through the capillaries Virtually all nutrients, including all amino acids and sugars, enter the body by crossing the enterocytes (the absorptive cells found in the small intestine) that make up the epithelium layer that covers each and every villi. There are two routes by which molecules make their way from small intestine into the bloodstream: -The transcellular route -across the plasma membrane of the enterocytes.
-The paracellular route -across tight junctions between the enterocytes.
For most part, the tight junctions of the Para cellular route are impermeable to large organic molecules such as dietary amino acids and glucose (mm) Those types of molecules are transported exclusively by the transcellular route. Transcellular absorption of nutrients can take place by active transport or by diffusion. Diffusion occurs simply through random molecular movement.
Fats, instead of diffusing into the capillaries, make their way into the lacteals, the lymphatic vessels present in each villus. From there, they drain from the intestine and rapidly flow through the lymphatic system and ultimately into the bloodstream by way of the thoracic duct. Lymphatic capillaries are present in almost every tissue of the body.
Only a few regions, including the epidermis of the skin, the mucous membranes, the bone marrow, and the central nervous system, are free of lymphatic capillaries, whereas regions such as the lungs, gut, genitourinary system, and dermis of the skin are densely packed with these vessels.
The key to the absorption of most nutrients in the small intestine is the electrochemical pump powered by electrolytes (mainly sodium). Every single cell in the body is required to maintain a low concentration of sodium inside the cell (with a correspondingly high concentration of sodium out of the cell for the purpose of osmosis) which is required for the movement of nutrients into the cell and waste out.
The blood vessel absorb the nutrients from the villi and carry them to the veins in two ways: 1 through the portal vein into the liver, where it penetrates every part of the liver, then passes out through the hepatic vein into the veins near the heart and 2nd through the lacteals, and empty into the subclavian vein. Then, the venous blood, supplied from the lacteals with new material, enters the heart and out through the pulmonary artery into the lungs, where, as purple venous blood, it penetrates the most remote capillaries. If the lungs be full of fresh air, the oxygen changes the purple blood into red blood, and burns up the impurities. The waste products of the combustion of carbon and hydrogen are expelled from the lungs at every breath in the form of C02 and H20 vapour; and not until now can the nutritional elements in the blood, obtained from the food, become in reality food, or perfect blood.
SUMMARY OF THE INVENTION
The invention provides a number of features that has found to have the potential of administering a dose of essential nutrient(s) in conjunction with or without conventional drugs most suited but not limited to bypassing conventional ways of administration. The invention provided herein is for inhalational nutrient(s) for nutritional purposes.
There is provided an atypical method of providing nutrients to the organism bypassing the conventional digestive system. This allows for a novel way of providing the organism with the essential nutriments required by the body through inhalation with added benefit of allowing the nutriments to bypass the first-pass metabolism and therefore nutrients are absorbed directly into the systemic circulation for an instantaneously parenteral action. Moreover, by bypassing the GI tract, a much smaller dose can be administered with the same effect of a conventional intake of supplements through the digestive track.
The invention herein discloses an advantageous process of bypassing the GI tract and therefore gaining a direct access to the red blood. This process can be use when states arise from suspected abnormality in absorption of food nutrients across the gastrointestinal (GI) tract but also for a wider range of situation wherein the added benefit of direct nutritional absorption is preferred. Moreover, the manufacturing of such content compound alongside conventional drugs or recreational elements could give the health conscious users a sense of well-being.
The nutrient(s) contained in the content compound must be processed using known techniques to break down the nutritional compounds to their simplest form, one that can be readily found in the blood and conglomerate them to a specific size for optimum diffusion. Only then the content compound can be integrated in device for inhalation.
Example of simple form nutrients can be simple sugars, amino-acids, fatty acids, any of the thirteen vitamins and sixteen essential minerals. Method of combining nutritional content compound can include a preparation of a solution for an aerosol form and powder form for readily mixing the nutrient(s) with conventional inhaling products found in conventional devices such as but not limited to nebulizer, meter-dose inhaler, dry powder inhaler, capsule, vaporizer, medical ventilator, nasal spray, etc. The lung deposition characteristics and efficacy of an aerosol depend largely on the particle and droplet size. Generally the smaller the particle is the greater its chance of peripheral penetration and retention. However, for very fine particle below O.5um in diameter, there is a chance of avoiding deposition altogether and being exhaled.
Studies have suggested that particles of more than 10 urn in diameter are rnost likely to deposit in the mouth and throat, for those of 5-bum diarneter a transition from rnouth to airways deposition occurs, and particles smaller than Sum in diameter deposit more frequently in the lower airways and are more appropriate for pharmaceutical aerosols.
Olfactory transfer can be used for delivery of drugs that have a required effect in the central nervous system. [such as B vitamins complex.] The present invention could find its way to the ever increasing electronic cigarette market wherein the inhaling product could contains all sort of nutrients mainly vitamin(s) and/or mineral(s) proven to be beneficial to the health with the added effect of targeting certain conditions associated with a lack of vitamin(s) and/or shown to be treated with vitamin(s). A wide range of products can be developed per each family of nutrients.
The invention described herein could also be used alongside conventional inhaled drugs such as nicotine. It has been shown that vitamins C helps with the protection of the lining of the lungs and therefore the addition of the aforementioned macronutrient within the composition of the vaporizer would create a totally new product to market for the pharmaceutical and /or the e-cigarette industry.
Last but not least, dedicated sprays, inhalers and/or vaporizer could be developed to offer nutritional complements with added benefit of virtually instantaneous absorption of said nutrients for a wide range of use from sports enthusiasts to medically impaired patient to more critical scenarios such as long space missions where nutrition plays an essential role in the health and safety of the astronauts.
Claims (1)
- Claims: 1 -A content compound element comprising of at least one or more of any organic nutrient(s) such as carbohydrate, fats, protein (or amino acids), vitamins, inorganic S compounds such as dietary minerals, macro nutrient, micronutrient, nutrient and/or electrolyte which is formulated for inflation into the respiratory apparatus.2 -Any nutrients of claim 1 wherein said nutrient is in form readily absorbable in the blood stream by diffusion through the respiratory apparatus.3 -A content component as per claim 1 to 2 wherein the nutritional compound is composed of material powder or liquid inhalant carried into the respiratory passages by devices such as aerosols, nebulizer, vaporizer and any other apparatus use for inhaling a content compound.4 -A content component as per claim 1 to 3 wherein the said element can be insuff late nasally for the purpose of intranasal absorption through the mucous membrane.5 -A content component as per claim 4 wherein the said element can be insuff late nasally for the purpose of a systemic effect.6 -A nutritional element according to claim 1 to 5 wherein the nutritional content components particles has a diameter comprise between 5-10 um or lesser than Sum.7 -A nutritional content component according to claims 1 wherein the absorbable nutrient(s) molecules are processed in a conglomerate to have a diameter between 5 and 10 um or lesser than 5 um.8 -A content compound according to any preceding claims wherein the nutritional content compound gains direct access to red blood bypassing all conventional way of absorption.9 -A content component according to any proceeding claims wherein the nutrients can be supplied alongside recreational element in apparatus such as vaporizer.-A content component according to any proceeding claims wherein the nutritional content component can be supplied alongside conventional medicine.S11 -A content compound according to any proceeding claims wherein the inhaled nutritional content compound is absorbed in the body instantaneously.12 -A Liquid for a vaporizer wherein the content compound of the liquid for vaporizing in the respiratory tract contains at least one or more nutrient(s) as per described in any of the preceding claims.13 -A powder for an inhaler wherein the content compound of the powder for inhalation contains at least one or more nutrient(s) as described in any of the preceding claims.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1407554.3A GB2525626A (en) | 2014-04-29 | 2014-04-29 | Composition and method for inhalable nutritional element |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1407554.3A GB2525626A (en) | 2014-04-29 | 2014-04-29 | Composition and method for inhalable nutritional element |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201407554D0 GB201407554D0 (en) | 2014-06-11 |
GB2525626A true GB2525626A (en) | 2015-11-04 |
Family
ID=50972073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1407554.3A Withdrawn GB2525626A (en) | 2014-04-29 | 2014-04-29 | Composition and method for inhalable nutritional element |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2525626A (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5556611A (en) * | 1988-05-04 | 1996-09-17 | Hermes Fabrik Pharmazeutischer Praparate | Vitamin A aerosol-inhalant preparations and method |
US5944012A (en) * | 1996-03-25 | 1999-08-31 | Pera; Ivo E. | Method for dispensing antioxidant vitamins by inhalation background of the invention |
WO2001015777A1 (en) * | 1999-08-31 | 2001-03-08 | Oxycal Laboratories, Inc. | Pulmonary-administration of mineral ascorbates |
EP1238665A1 (en) * | 2001-03-05 | 2002-09-11 | Ivo Pera | Method for dispensing s-adenosyl-methionine in a micro fine powdered form by inhalation |
WO2003000326A1 (en) * | 2001-06-20 | 2003-01-03 | Nektar Therapeutics | Powder aerosolization apparatus and method |
US20100200008A1 (en) * | 2009-02-09 | 2010-08-12 | Eli Taieb | E-Cigarette With Vitamin Infusion |
US20130220315A1 (en) * | 2009-07-27 | 2013-08-29 | Fuma International Llc | Electronic vaporizer |
-
2014
- 2014-04-29 GB GB1407554.3A patent/GB2525626A/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5556611A (en) * | 1988-05-04 | 1996-09-17 | Hermes Fabrik Pharmazeutischer Praparate | Vitamin A aerosol-inhalant preparations and method |
US5944012A (en) * | 1996-03-25 | 1999-08-31 | Pera; Ivo E. | Method for dispensing antioxidant vitamins by inhalation background of the invention |
WO2001015777A1 (en) * | 1999-08-31 | 2001-03-08 | Oxycal Laboratories, Inc. | Pulmonary-administration of mineral ascorbates |
EP1238665A1 (en) * | 2001-03-05 | 2002-09-11 | Ivo Pera | Method for dispensing s-adenosyl-methionine in a micro fine powdered form by inhalation |
WO2003000326A1 (en) * | 2001-06-20 | 2003-01-03 | Nektar Therapeutics | Powder aerosolization apparatus and method |
US20100200008A1 (en) * | 2009-02-09 | 2010-08-12 | Eli Taieb | E-Cigarette With Vitamin Infusion |
US20130220315A1 (en) * | 2009-07-27 | 2013-08-29 | Fuma International Llc | Electronic vaporizer |
Also Published As
Publication number | Publication date |
---|---|
GB201407554D0 (en) | 2014-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10034996B2 (en) | Inhalation systems, breathing apparatuses, and methods | |
US10300226B2 (en) | Rescue inhaler | |
Scheuch et al. | Novel approaches to enhance pulmonary | |
JP6293732B2 (en) | Method and system for administering pulmonary surfactant by nebulization | |
US20090197941A1 (en) | Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease | |
US20210330635A1 (en) | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection | |
ES2554108T3 (en) | Methods of treatment of necrotizing enterocolitis | |
ES2712600T3 (en) | Improved method and system for the administration by atomization of a pulmonary surfactant | |
KR20010020346A (en) | Method of delivering halotherapy | |
CN115955965A (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
Lampland et al. | Aerosolized KL4 surfactant improves short‐term survival and gas exchange in spontaneously breathing newborn pigs with hydrochloric acid‐induced acute lung injury | |
WO2023065833A1 (en) | Oxygen capsule, and preparation method therefor and application thereof | |
US20170312474A1 (en) | Ingestible compositions system and method | |
CN103462942B (en) | A kind of suction ambroxol hydrochloride solution | |
US20190328699A1 (en) | Ingestible compositions system and method | |
ES2987461T3 (en) | Medical gas mixture | |
GB2525626A (en) | Composition and method for inhalable nutritional element | |
CN101897719B (en) | Medical composite used for treating smoke inhalation lung injury | |
El-Shimy et al. | Non invasive ventilation versus synchronized intermittent mandatory ventilation with pressure support in weaning of COPD patients: comparative study | |
CN103919789A (en) | Ultrasonic atomization steam inhalation treatment method of ephedrine composition | |
JP2018094375A (en) | Systems for administering platelet rich plasma solution by inhalation to individual | |
JP2022096664A (en) | Molecular hydrogen-containing composition for maintaining lung function in human lung cancer and/or improving reduction in lung function attributed to human lung cancer | |
CN209378230U (en) | Physiotherapy device for department of respiration | |
Pereira et al. | Inhalotherapy in Noninvasive Ventilation | |
EP4146189A1 (en) | Glyceryltriacetate (gta) for use in improving breathing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |